about
Botulinum Toxin A and Lower Urinary Tract Dysfunction: Pathophysiology and Mechanisms of ActionTreatment of painful bladder syndrome/interstitial cystitis with botulinum toxin A: why isn't it effective in all patients?Presence of Cleaved Synaptosomal-Associated Protein-25 and Decrease of Purinergic Receptors P2X3 in the Bladder Urothelium Influence Efficacy of Botulinum Toxin Treatment for Overactive Bladder SyndromeLong-Term Efficacy and Safety of Repeated Intravescial OnabotulinumtoxinA Injections Plus Hydrodistention in the Treatment of Interstitial Cystitis/Bladder Pain SyndromeDoes Reduction of Number of Intradetrusor Injection Sites of aboBoNTA (Dysport®) Impact Efficacy and Safety in a Rat Model of Neurogenic Detrusor Overactivity?Intravesical Botulinum Toxin A Injections for Bladder Pain Syndrome/Interstitial Cystitis: A Systematic Review and Meta-Analysis of Controlled StudiesPurinergic signalling in the urinary tract in health and disease.Intradetrusor onabotulinumtoxinA for overactive bladder.Botulinum toxin in urology: a review of clinical potential in the treatment of urologic and sexual conditions.Innovative pharmacotherapies for women with overactive bladder: where are we now and what is in the pipeline?Advances in diagnosis and treatment of interstitial cystitis/painful bladder syndrome.Current and potential urological applications of botulinum toxin A.Disease-Specific Outcomes of Botulinum Toxin Injections for Neurogenic Detrusor Overactivity.Bladder pain induced by prolonged peripheral alpha 1A adrenoceptor stimulation involves the enhancement of transient receptor potential vanilloid 1 activity and an increase of urothelial adenosine triphosphate release.Expression of cleaved SNAP-25 after bladder wall injection of onabotulinumtoxina or abobotulinumtoxina: A comparative study in the mice.Purinergic Signalling: Therapeutic Developments.Characterizing the Bladder's Response to Onabotulinum Toxin Type A Using a Rat Model.Retrograde transport of radiolabelled botulinum neurotoxin type A to the CNS after intradetrusor injection in rats.Reduction of urgency severity is the most important factor in the subjective therapeutic outcome of intravesical onabotulinumtoxinA injection for overactive bladder.
P2860
Q26750535-6D44B8AB-7B6C-4302-9290-1D3B9CA8BF6EQ26773579-2F5AC6FC-B636-444F-80C0-8FD595C72321Q35737565-7584ED2A-E57C-4F9D-80BE-304B66250478Q36226899-437DE9B5-E4FF-4DDC-9297-98AB997C675AQ36401506-B4EA53EF-7367-46D7-B8AE-9424B5ED68A6Q37275119-E15294CF-0C2D-4BAA-AEFF-40A16FC9B6D4Q37620260-DEC7982C-4506-4262-A92C-5962C65A0892Q38198733-343AE0BD-740D-4C82-915F-F42A7A9094E5Q38262923-08734DE2-EAE3-4709-BE43-A3A5AF27334BQ38265873-33172B35-313B-477C-824D-6EE836AFC73DQ38270526-879CD90D-6FFD-4022-A610-3DC5C025710EQ38564108-2EFD8186-116B-48F8-AE1D-DD223BB7CFD7Q38675157-95516B05-E399-4F7F-8963-03C2A5B924C6Q40628033-BC386826-6E7F-4ACE-A216-9545DA0F45DDQ40949732-251527A4-9E83-41FC-BB99-1E95F99D97EEQ42367885-08CD79E7-AF58-486D-B1D0-C0AF6131A1BFQ42721526-C95F3682-61D8-47E0-A9BA-4344CEE0B182Q51030193-5FBA5031-6BDC-441E-9784-28B3455CA286Q53655799-526CFC79-5C8F-40A6-AB68-2416230CD61D
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Targets for botulinum toxin in the lower urinary tract.
@en
type
label
Targets for botulinum toxin in the lower urinary tract.
@en
prefLabel
Targets for botulinum toxin in the lower urinary tract.
@en
P2860
P356
P1476
Targets for botulinum toxin in the lower urinary tract.
@en
P2093
Francisco Cruz
P2860
P356
10.1002/NAU.22445
P577
2013-06-17T00:00:00Z